FIGURE 3.

Glycaemic efficacy of tirzepatide in SURPASS 1‐5. ⁵⁶ , ⁷⁵ , ⁷⁶ , ⁷⁷ , ⁷⁸ , ⁸⁷ Data are estimated mean (SE) or percentage and from the modified intention‐to‐treat population (efficacy analysis set) of each study. (A) HbA1c change from baseline to the primary study endpoint; proportion of participants achieving HbA1c targets (B) <7.0%, (C) ≤6.5% and (D) <5.7%. *p < .05 versus placebo or active comparator. HbA1c, glycosylated haemoglobin A1c; IDeg, insulin degludec; IGlar, insulin glargine 100 U/ml; MET, metformin; N, number of patients who were randomly assigned and received at least one dose of study drug; PBO, placebo; Sema, semaglutide; SGLT‐2i, sodium‐glucose cotransporter‐2 inhibitor; SU, sulphonylurea